However, acquired resistance to BRAF-targeted therapies in BRAF-mutated CRC is a significant challenge, but it may potentially be overcome using combinations of anti-BRAF and anti-EGFR therapies with inhibitors of MEK, Wnt, or cyclin-dependent kinases CDK4/6 [29]. Here, MAP2K7 is linked to colorectal carcinoma.